A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria

PHASE2TerminatedINTERVENTIONAL
Enrollment

127

Participants

Timeline

Start Date

October 26, 2022

Primary Completion Date

December 27, 2023

Study Completion Date

April 18, 2024

Conditions
Chronic Spontaneous Urticaria
Interventions
DRUG

Lirentelimab (AK002)

Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8

OTHER

Placebo

Placebo

Trial Locations (67)

11021

Allakos Investigational Site 227-007, Great Neck

11203

Allakos Investigational Site 227-022, Brooklyn

12203

Allakos Investigational Site 227-201, Berlin

17033

Allakos Investigational Site 227-028, Hershey

19103

Allakos Investigational Site 227-040, Philadelphia

21162

Allakos Investigational Site 227-063, White Marsh

21204

Allakos Investigational Site 227-012, Towson

21224

Allakos Investigational Site 227-019, Baltimore

21614

Allakos Investigational Site 227-214, Buxtehude

28801

Allakos Investigational Site 227-002, Asheville

29420

Allakos Investigational Site 227-066, North Charleston

31904

Allakos Investigational Site 227-018, Columbus

32256

Allakos Investigational Site 227-036, Jacksonville

33135

Allakos Investigational Site 227-062, Miami

33607

Allakos Investigational Site 227-067, Tampa

33613

Allakos Investigational Site 227-005, Tampa

34239

Allakos Investigational Site 227-041, Sarasota

35058

Allakos Investigational Site 227-068, Cullman

35209

Allakos Investigational Site 227-024, Birmingham

40509

Allakos Investigational Site 227-051, Lexington

43235

Allakos Investigational Site 227-043, Columbus

43617

Allakos Investigational Site 227-064, Toledo

45229

Allakos Investigational Site 227-013, Cincinnati

45236

Allakos Investigational Site 227-029, Cincinnati

46168

Allakos Investigational Site 227-074, Plainfield

48106

Allakos Investigational Site 227-034, Ann Arbor

48202

Allakos Investigational Site 227-032, Detroit

48346

Allakos Investigational Site 227-070, Farmington Hills

49074

Allakos Investigational Site 227-206, Osnabrück

53228

Allakos Investigational Site 227-033, Greenfield

55128

Allakos Investigational Site 227-210, Mainz

55131

Allakos Investigational Site 227-202, Mainz

55905

Allakos Investigational Site 227-052, Rochester

56529

Allakos Investigational Site 227-073, Dilworth

59808

Allakos Investigational Site 227-059, Missoula

60305

Allakos Investigational Site 227-057, River Forest

60590

Allakos Investigational Site 227-208, Frankfurt

61761

Allakos Investigational Site 227-045, Normal

63141

Allakos Investigational Site 227-008, St Louis

64297

Allakos Investigational Site 227-205, Darmstadt

66211

Allakos Investigational Site 227-047, Overland Park

73170

Allakos Investigational Site 227-060, Oklahoma City

78759

Allakos Investigational Site 227-055, Austin

79903

Allakos Investigational Site 227-049, El Paso

80802

Allakos Investigational Site 227-211, Munich

80907

Allakos Investigational Site 227-006, Colorado Springs

83706

Allakos Investigational Site 227-045, Boise

84107

Allakos Investigational Site 227-039, Murray

Allakos Investigational Site 227-071, Murray

85021

Allakos Investigational Site 227-014, Phoenix

85251

Allakos Investigational Site 227-023, Scottsdale

86179

Allakos Investigational Site 227-204, Augsburg

89129

Allakos Investigational Site 227-207, Langenau

90025

Allakos Investigational Site 227-026, Los Angeles

90045

Allakos Investigational Site 227-009, Los Angeles

90404

Allakos Investigational Site 227-021, Santa Monica

91054

Allakos Investigational Site 227-209, Erlangen

91786

Allakos Investigational Site 227-031, Upland

92691

Allakos Investigational Site 227-011, Mission Viejo

93301

Allakos Investigational Site 227-058, Bakersfield

97223

Allakos Investigational Site 227-027, Portland

02111

Allakos Investigational Site 227-016, Boston

04103

Allakos Investigational Site 227-203, Leipzig

Unknown

Allakos Investigational Site 227-302, Lodz

Allakos Investigational Site 227-304, Lodz

Allakos Investigational Site 227-303, Lublin

Allakos Investigational Site 227-301, Zabrze

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Allakos Inc.

INDUSTRY

NCT05528861 - A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria | Biotech Hunter | Biotech Hunter